Abstract MDMA, an addictive psychostimulant-consumed worldwide, has the ability to induce neurotoxic effects and addiction in laboratory animals and in humans through its effects on monoaminergic systems. MDMAinduced neurotoxicity in mice occurs primarily in dopaminergic neurons and does not significantly affect the serotonergic system. As the neurotoxic effects of MDMA in mice involve excessive dopamine (DA) release, DA receptors are highly likely to play a role in MDMA neurotoxicity, but the specific dopamine receptor subtypes involved have not previously been determined definitively. In this study, dopamine D1 and D4 receptor knock-out mice (D1R -/-and D4R -/-) were used to determine whether these receptors are involved in MDMA neurotoxicity. D1R inactivation attenuated MDMA-induced hyperthermia, decreased the reduction of dopamine and dopamine metabolite levels, and protected against dopamine terminal loss and reactive astrogliosis as determined in the striatum, 7 days after MDMA treatment. In sharp contrast, inactivation of D4R did not prevent hyperthermia or the neurotoxic effects of MDMA. Altogether, these results indicate that D1R, but not D4R, plays a significant role in the dopaminergic striatal neurotoxicity observed after exposure to MDMA.
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MDMA is an indirect monoaminergic agonist (Schmidt 1987) . The neurotransmitter system affected by MDMA neurotoxicity differs depending on the species studied. In rats and primates, MDMA toxicity primarily affects the serotonergic system, although in rats, dopamine terminals can also be affected to a lesser extent (Capela et al. 2009; Jensen et al. 1993; Schmidt 1987) . In mice, MDMA mainly damages the dopaminergic system (Green et al. 2003; Granado et al. 2008a, b) , causing degeneration of dopamine terminals in the striatum, as has been shown by silver staining (O'Callaghan and Miller 1994) , a marker of toxicity that provides excellent visualization of degenerating neurons (Ares-Santos et al. 2013b ). These neurotoxic effects are dose dependent and are also reflected by decreases in the concentration of dopamine (DA) and its main metabolites, and decreases in dopamine transporter (DAT) and tyrosine hydroxylase (TH)-immunoreactive (ir) fibers in the striatum (Green et al. 2003; Fornai et al. 2005; Granado et al. 2008a, b) . These neurotoxic effects are persistent: despite some timedependent recovery of dopamine terminals in the striatum, TH-and DAT-immunoreactivity remain reduced even 1 month after treatment with MDMA (Granado et al. 2008b) .
MDMA also causes cell body loss in the substantia nigra, confirming the persistence of neurotoxic effects in the striatum (Granado et al. 2008b ). In addition, MDMA induces death of striatal GABAergic neurons, which were found to have neuronal inclusions (Fornai et al. 2002 (Fornai et al. , 2003 . Dopamine itself is implicated in methamphetamine and MDMA neurotoxicity in the dopaminergic system (Capela et al. 2009; Fornai et al. 2002 Fornai et al. , 2003 Fornai et al. , 2004 Ares-Santos et al. 2012 , 2013a Granado et al. 2011a Granado et al. , b, 2013 Moratalla et al. 2014) . In particular, it has been shown that cytosolic dopamine is the primary source of reactive oxygen species (ROS), superoxide and hydroxyl radicals in methamphetamine and MDMA neurotoxicity (Cadet and Brannock 1998; Capela et al. 2009; Krasnova and Cadet 2009; LaVoie and Hastings 1999) . Moreover, pharmacological studies using D1/D5 or D2-D4 antagonists have demonstrated significant reduction of amphetamine derivative-induced toxicity (Albers and Sonsalla 1995; Eisch and Marshall 1998; Metzger et al. 2000; Xu et al. 2005) . We have recently shown that the D2R is specifically involved in MDMA-and methamphetamineinduced neurotoxicity (Granado et al. 2011a ). In addition to reducing hyperthermia, D2R inactivation decreases cytosolic dopamine by reducing dopamine uptake (Granado et al. 2011a ). Thus, it is possible that the protective effects seen after pharmacologic blockade of D2/D3/D4R are not only due to D2R but to the implication of the other two receptors, D3R or D4R, as well, because their contributions have not been established. Similarly, we have determined that D1R is necessary for methamphetamine-induced neurotoxic effects (Ares-Santos et al. 2012 ), but its role in MDMA neurotoxicity in mice has not been elucidated.
Although, MDMA does not produce dopaminergic neurotoxicy in humans, understanding the molecular mechanisms of dopamine vulnerability can be useful to unravel the neurotoxic effects of other amphetamine-type stimulants that do damage the dopaminergic system in humans, as well as to provide important clues of susceptibility of dopamine neurons in neurodegenerative diseases. In this study, our aim was to unravel the roles of the D1R and D4R subtypes in MDMA-induced neurotoxicity. For that purpose, we studied the effects of a neurotoxic MDMA regimen (three injections of 30 mg/kg given 3 h apart) on the hyperthermic response and the loss of dopaminergic terminals and glial response in the striatum of D1R or D4R knockout (D1R -/-, D4R -/-) mice compared with their respective WT littermates.
Materials and Methods

Animals and Treatment
Experiments were carried out in male and female dopamine D1 and D4 receptor knockout (D1R -/-and D4R -/-) mice generated by homologous recombination as previously described (Moratalla et al. 1996; Rubinstein et al. 1997; Xu et al. 1994 ) and in their wild type (WT) littermates (WT D1R
?/? and WT D4R ?/? ). The mice used in this study were derived from mating heterozygous mice (Granado et al. 2008c; Ortiz et al. 2010) . We used adult males and females initially weighing 20-25 g whose genotype was determined by PCR analysis. Mice were housed in groups of 4-6 per cage, in conditions of constant room temperature (21-22°C) and a 12-h light/dark cycle (lights on at 7:00 a.m.), and given free access to food and water. Animals were treated in accordance with European Community guidelines (2003/65/ CE), and all experimental procedures were approved by the Bioethics Committee of the Instituto Cajal.
Mice received three injections of (±)-MDMA (30 mg/kg) or saline (control) at 3 h intervals, a neurotoxic regimen previously shown to produce marked depletion of mouse striatal DA. The drug was dissolved in 0.9 % w/v NaCl (saline) and a volume of 10 ml/kg was injected. MDMA hydrochloride was obtained from the National Institute of Drug Abuse (NIDA, Research Triangle Park, North Carolina, USA). Doses are quoted in terms of the base. Animals were sacrificed 7 days after drug administration.
Measurement of Rectal Temperature
Rectal temperature was measured using a digital readout thermocouple (BAT-12 thermometer, Physitemp Instruments, Clifton, NJ, USA) with a resolution of 0.1°C and an accuracy of ±0.1°C attached to a RET-3 Rodent Sensor. The sensor was inserted 2 cm into the mouse rectum while the mouse was lightly restrained by holding it with the hand. A steady readout was obtained within 5-7 s of probe insertion. Temperature readings were taken every 30 min for 1 h before the first MDMA injection to establish baseline temperature (three readings). Then, temperature was registered at 30 min, 1, 2, and 3 h after each MDMA administration for the first and second injections and 30 min and 1 h after the third MDMA injection, resulting in a total of 13 readings for each mouse.
Measurement of Monoamines and Their Metabolites in the Striatum
Seven days after the treatment, mice were killed by cervical dislocation and decapitation (n = 4-6 per group). Brains were rapidly removed and the striatum dissected out on ice following the classic procedure described by Iversen and Glowinski (1966) to study the levels of catecholamines and their metabolites in different brain regions. Striatal tissue was weighed and stored at -80°C for subsequent use. Levels of dopamine (DA), serotonin (5-HT), and their metabolites 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 5-hydroxyindolacetic acid (5-HIAA) were measured by high-performance liquid chromatography and electrochemical detection as described previously (Granado et al. 2010; Urrutia et al. 2013) . The mobile phase consisted of KH 2 PO 4 (0.05 M), octanesulfonic acid (0.4 mM), EDTA (0.1 mM), and methanol (16 %) and was adjusted to pH 3.7 with phosphoric acid, filtered, and degassed. The flow rate was 1 ml/min. The high-performance liquid chromatography system consisted of a pump (Waters 510) linked to an automatic sample injector (Loop 200 ll, Waters 717 plus Autosampler) and a stainless steel reversed-phase column (Spherisorb ODS2, 5 lm, 150 9 4.6 mm 2 ; Waters, Milford, MA, USA) with a precolumn and a coulometric detector (Coulochem II; ESA, Chelmsford, MA, USA). The working electrode potential was set at 400 mV with a gain of 2 lA. The current produced was monitored by means of integration software (Clarity Software, DataApex, Prague, Czech Republic).
Immunohistochemistry
Mice (n = 4-6 per group) were sacrificed 7 days after treatment with three injections of 30 mg/kg MDMA. The animals were deeply anaesthetized with sodium pentobarbital (50 mg/kg, i.p.) and then transcardially perfused with 4 % paraformaldehyde dissolved in PB (phosphate buffer, pH 7.4). After perfusion, brains were removed and immersed overnight in the same fixative solution. Coronal brain sections (30 lm) were obtained on a slicing vibratome (Leica, Madrid, Spain) and kept in PB solution at 4°C until use.
Immunostaining was carried out on free-floating sections with standard avidin-biotin immunocytochemical protocols (Darmopil et al. 2008 (Darmopil et al. , 2009 Pavon et al. 2006; Rodrigues et al. 2007 ). Endogenous peroxidase activity was arrested via incubation in 3 % H 2 O 2 for 10 min. Sections were preblocked for 1 h with normal goat serum (NGS) (Vector Laboratories, Burlingame, CA). Primary antibodies (Ab-I) were: rabbit tyrosine hydroxylase antiserum (TH, used at 1:1000 Chemicon International, Temecula, CA, USA); rat monoclonal antibody against dopamine transporter (DAT, used at 1:1000, Chemicon International); and rabbit antiglial fibrillary acidic protein antibody (GFAP, used at 1:1000, DakoCytomation, Denmark). All primary antibodies were prepared in buffer phosphate with triton (PBST) solutions containing NGS. After careful washing, sections were incubated with the appropriate secondary biotinylated antiserum (Vector) at room temperature and developed using diaminobenzidine (DAB). The reaction was monitored every 5 min using an optical microscope (Leica). After washing, sections were mounted on gelatin-coated slides, air-dried, and dehydrated in ascending concentrations of ethanol, then cleared with xylene and cover slipped under Permount.
Quantification of TH and DAT expression was carried out using an image analysis system (Analytical Imaging Station (AIS), Imaging Research Inc., Linton, UK) with a 59 lens. Color intensities were converted to grayscale, and the ratio of stained area in the striatum of treated animals to that in untreated animals was calculated (Darmopil et al. 2008 (Darmopil et al. , 2009 Espadas et al. 2012; Granado et al. 2010 Granado et al. , 2011b .
Statistics
Data are presented as mean ± standard error of the mean (SEM). The results of rectal temperature measurements were analysed using two-way analysis of variance (ANOVA) for repeated measurements. Data obtained from image analysis of striatal TH and DAT immunostaining were analysed using two-way ANOVA. Significant differences were analyzed pair-wise by post hoc comparisons using the Newman Keuls and Tukey's tests to determine specific differences between groups. All statistical analyses were performed using the Sigma Stat 2.03 program and the threshold for statistical significance was set at p = 0.05. Graphical representations were obtained using the Sigma Plot 12.0 software.
Results
Hyperthermia Induced by MDMA was Inhibited in D1R
-/-Mice but not in D4R -/-Mice
In agreement with previous reports (Granado et al. 2008a (Granado et al. , b, 2011a , MDMA (30 mg/kg, three injections separated by 3 h) administration to WT D1R ?/? mice-induced significant peaks in rectal temperatures that were not seen following saline treatment. The highest temperatures were recorded 1 h after the second and third injections (Fig. 1) . In contrast, MDMA administration did not increase temperature in D1R
-/-animals after any of the drug injections (Fig. 1a) . In fact, there was a hypothermic response after the first MDMA injection, with average rectal temperature decreasing from 37.6 to 36.2°C. This hypothermic response was not observed after the second and third injections. Thus, there was a statistically significant difference in body temperature between WT D1R
?/? and D1R -/-animals following treatment with MDMA (p \ 0.05). It should be noted that the rectal temperatures of the saline-treated D1R -/-animals were slightly, but significantly, lower than those of saline-treated WT D1R
?/? mice (Fig. 1a) . No significant differences in either basal body temperature or body temperature after treatment with MDMA (30 mg/kg 9 3 injections separated by 3 h) were found between WT D4R
?/? and D4R -/-mice (Fig. 1b) . Both WT D4R
?/? and D4R -/-mice exhibited significant temperature increases following MDMA treatment (p \ 0.001 compared to saline-treated mice). Although the basal temperature was 38°C in WT D1R
?/? mice and 37°C in WT D4R
?/? mice, there were no differences between these two groups in the neurochemical data, indicating that this range of variation in basal body temperature does not affect the integrity of the dopaminergic system in saline-treated animals.
Inactivation of D1R, but not D4R, Attenuated MDMAInduced Decreases in TH Expression in the Striatum
Previous studies have shown that treatment with MDMA induces a decrease in the density of TH-immunoreactive fibers in the striatum of WT animals. Although this decrease is most prominent 1 and 7 days after MDMA administration, it persists for at least 1 month after treatment ends (Granado et al. 2008a) 
. Quantitative image analysis confirmed that in WT D1R
?/? mice striatal TH immunoreactive fiber (TH-ir) density at 7 days post-MDMA treatment was 84 % (Fig. 2) lower than in salinetreated mice (p \ 0.001). In contrast, D1R
-/-mice showed only a 25 % reduction in TH-ir fibers 7 days after MDMA treatment (p \ 0.001 compared to saline-treated D1R -/-), despite the lack of hyperthermia (Fig. 2) . The damage was mainly observed in the dorsolateral part of the striatum in agreement with our previous observations (Granado et al. 2008a ). There was no significant difference in TH-ir density between D1R -/-and WT D1R ?/? mice on treatment with saline, but the difference between the two groups following treatment with MDMA was significant (p \ 0.001) (Fig. 2) . In contrast, there was no significant difference between TH-ir fiber density in WT D4R
?/?
and D4R -/-mice following treatment with saline or with MDMA, indicating that D4R is not required for MDMA damage.
Genetic Inactivation of D1R, but not D4R, Attenuated MDMA-Induced Loss of DAT Expression in the Striatum
In agreement with the loss of striatal TH-ir, MDMA treatment induced significant decreases in DAT-ir in WT D1R
?/? animals (81 %) 7 days after MDMA compared to saline-treated mice (p \ 0.001). However, in D1R -/-mice (Fig. 3) , we observed only a 15 % reduction in DAT-ir compared to saline-treated mice (p \ 0.05). There was a significant difference between WT D1R
?/? and D1R
-/-
Fig. 1 MDMA-induced hyperthermia was inhibited in D1R
-/-mice but not in D4R -/-mice. MDMA (30 mg/kg) (i.p., every 3 h, 93) induced hyperthermic response in WT D1R
?/? mice while it failed to produce hyperthermia in D1R -/-mice, which showed hypothermia after the first injection (a). MDMA also produced a hyperthermic response in D4R -/-mice (b). Arrows indicate drug injections. n = 6-8 per group. Data represents the mean ± SEM. Statistical differences between WT versus MDMA-treated animals are indicated. *p \ 0.05 and **p \ 0.001 ?/? mice, but this process did not occur in D4R -/-mice. Data represents the mean ± SEM, n = 6-8 per group, **p \ 0.001 versus saline, DD p \ 0.001 versus WT MDMA-treated mice. Bar indicates 500 lm MDMA-treated mice. Bar indicates 500 lm mice treated with MDMA (p \ 0.001), but no difference in baseline DAT-ir between saline-treated WT D1R
?/? and D1R -/-mice. There was no significant difference in DATir between D4R
-/-and WT D4R ?/? mice following treatment with MDMA or treatment with saline (Fig. 3) .
Inactivation of D1R Attenuated MDMA-Induced Loss of Monoamines in the Striatum
Basal levels of dopamine and its metabolites DOPAC and HVA were lower in D1R
-/-animals than in their WT D1R
littermates: dopamine 7 % lower; DOPAC 27 % lower; and HVA 43 % lower (p \ 0.05, Fig. 4) . Inactivation of D1R almost completely blocked MDMA-induced DA depletion 7 days after treatment (Fig. 4) . There was an 80 % reduction in DA levels in MDMA-treated WT D1R ?/? animals compared with saline-treated mice (p \ 0.005). For D1R -/-mice, the decrease was only 40 % (p \ 0.05), (Fig. 4) . Dopamine metabolites DOPAC and HVA were not significantly attenuated in D1R
-/-animals after MDMA treatment (Fig. 4) . MDMA had no effect on the levels of striatal serotonin (5-HT) or its metabolite 5-HIAA in WT D1R
?/? or D1R -/-mice (Fig. 4) .
MDMA-Induced Astrogliosis in the Striatum was Inhibited in D1R -/-Mice
In previous work, we have observed a correlation between damage and the increase in gliosis in the striatum after administration of amphetamine derivatives like MDMA or methamphetamine (Capela et al. 2009; Granado et al. 2008b Granado et al. , 2011a Gesi et al. 2004 ). Gliosis could be detected using Mac-1, a marker of reactive microglia, that peaks 1 day after MDMA, or GFAP, a marker of astrogliosis, that peaks at 3 days and continues activated for at least 1 week after treatment (Granado et al. 2011a; Ares-Santos et al. 2012; Tristão et al. 2013) . Therefore, we next checked whether inactivation of D1R also inhibits the MDMAinduced increase in gliosis using GFAP as a marker bearing in mind that our animals were sacrificed 7 days after treatment. As expected, the increase in GFAP seen after administration of MDMA to WT D1R ?/? mice was almost completely absent in D1R -/-mice (Fig. 5) , indicating that the reduction in gliosis correlates with the decrease in terminal loss after D1R inactivation.
Discussion
This study shows that D1R -/-mice are protected against MDMA-induced dopaminergic neurotoxity. Inactivation of D1R prevented the loss of dopamine, dopamine metabolites, and TH-and DAT-ir in the striatum 7 days after MDMA administration. In addition, GFAP-ir was less pronounced in the striatum of D1R -/-mice than in WT D1R ?/? mice following MDMA administration; clearly indicating that reactive astrogliosis was also reduced by D1R inactivation. In contrast, D4R
-/-mice did not differ from WT D4R
animals in terms of susceptibility to the neurotoxic effects of the drug. These findings confirm that dopamine D1R, but not D4R, is involved in MDMA-induced neurotoxicity. The term toxicity is used here to refer to neuronal cell damage and/or long-lasting alteration of function to encompass all of these long-term effects. One potential mechanism of D1R inactivation-induced protection against MDMA is the hypothermic response. Genetic inactivation of D1R prevented MDMA-induced hyperthermia, an important factor in the toxic response to the drug (Green et al. 2003 Colado et al. 2004) , although not critical. Previous reports have indicated that a D1/D5R antagonist blocked MDMA-induced hyperthermia (Benamar et al. 2008; Vanattou-Saïfoudine et al. 2010 ) and have shown increased DA levels in the preoptic anterior hypothalamus, a region associated with thermoregulation (Benamar et al. 2008) . These studies and our results with D1R -/-animals conclusively demonstrate that the D1R subtype is required for the MDMA-induced hyperthermic response as indicated previously (Ares-Santos et al. 2012) . Similarly, we have previously demonstrated that D2R is also implicated in the hyperthermic response to MDMA (Granado et al. 2011a) . Hyperthermia can potentiate the neurotoxic activity of amphetamines by promoting DAT function (Xie et al. 2000) and favouring the production of free radicals and the oxidation of DA in the brain (Kil et al. 1996; LaVoie and Hastings 1999; Spencer et al. 2002; Capela et al. 2009; Docherty and Green 2010) . However, hyperthermia is not always critically required for MDMAinduced dopaminergic neurotoxicity, as hypothermia does not always completely block MDMA neurotoxicity (Broening et al. 1995) .
We and others have previously used different approaches to dissociate temperature from toxicity. Attenuating hyperthermia has been shown to have no effect on MDMAinduced decreases in vesicular DA uptake and binding of the VMAT2 ligand dihydrotetrabenazine ( 3 [H] DHTBZ) (Hansen et al. 2002) , indicating it is not required for these deficits. Recent studies from our laboratory have also demonstrated that the protective effects of D1R inactivation against methamphetamine-induced neurotoxicity are not solely the result of blocking hyperthermia, as pretreatment with reserpine, which blocked methamphetamine-induced hyperthermia, potentiated neurotoxicity (Ares-Santos et al. 2012 , 2013a . Similarly, Friend and Keefe (2013) showed that intrastriatal infusion of SCH23390, a D1R antagonist, protects against methamphetamine neurotoxicity without affecting the hyperthermic response. Thus, although the hypothermic response in D1R -/-mice may contribute to the prevention of damage to dopaminergic terminals, other mechanisms are more likely to occur. It is possible that the effect of D1R inactivation increasing vesicular dopamine and reducing cytosolic dopamine, more directly contribute to the prevention of neurotoxicity.
Dopamine has been proposed to play a crucial role in MDMA-induced neurotoxicity. Treatment with MDMA produces an increase in cytosolic DA, which is metabolized and auto-oxidated, generating ROS such as hydrogen peroxide, hydroxyl radicals, DA quinones, superoxide anions, and hydrogen oxygen species, which generate oxidative stress and lead to mitochondrial dysfunction and damage in the dopaminergic terminal (Cadet and Brannock 1998; Capela et al. 2009; Krasnova and Cadet 2009; LaVoie and Hastings 1999) . Inhibition of mitochondrial complex I Fig. 5 Inactivation of D1R partially prevented MDMAinduced astrogliosis in mouse striatum. Photomicrographs of striatal sections from mice treated with saline or MDMA stained for GFAP in WT D1R
?/? and D1R -/-mice. Animals were killed 7 days after treatment. GFAP staining was greatly reduced in D1R -/-mice. n = 4-6 per group. Bar indicates 50 lm following MDMA could be the source of free radicals responsible for oxidative stress and the consequent neurotoxicity of this drug in mice (Puerta et al. 2010) .
Drugs that reduce DA availability prevent MDMAinduced ultrastructural alterations of striatal postsynaptic GABAergic cells (Fornai et al. 2002 (Fornai et al. , 2003 . Although the lower DA content and turnover in D1R -/-mice (Ares- Santos et al. 2012 Santos et al. , 2013a ) might lead to lower production of ROS after MDMA administration, contributing to the neuroprotective effect of D1R inactivation, this slight reduction in DA levels (7 %) is very unlikely to account for the robust protection, 75 % for TH and 85 % for DAT, against MDMA toxicity, indicating that other mechanisms must be involved. The protective effects seen in D1R -/-mice may also be related to the distribution of DA within the terminal, which differs from that in WT D1R
?/? mice. In previous experiments in our laboratory, D1R
-/-mice exhibited higher vesicular DA release and lower DA reuptake than WT D1R
?/? mice, despite their lower basal dopamine content, suggesting that D1R -/-animals store more DA in vesicles and therefore have a reduced cytosolic dopamine pool compared to their WT mice (Ares-Santos et al. 2012 , 2013a . Higher vesicular DA content would result in lower production of ROS after treatment with MDMA compared to WT D1R
?/? mice, providing a plausible reason for the reduction in MDMA-induced dopaminergic damage in D1R -/-mice. Astrogliosis, visualized by the induction of GFAP expression, is a hallmark of amphetamine derivativeinduced neurodegeneration (Johnson et al. 2004; O'Callaghan and Miller 1994; Granado et al. 2008b ) and dopaminergic terminal degeneration. D1R
-/-mice treated with MDMA exhibit not only reduced neurotoxicity, but also attenuated astroglial responses in the striatum. Most evidence indicates that astroglial activation occurs subsequent to neurotoxic changes in the striatum (Granado et al. 2008b; Antonelli et al. 2012) . This suggests that the reduced astrocyte activation observed with D1R inactivation does not imply that astroglial cells cannot be activated in the absence of D1R, but rather that reactive astrogliosis is reduced because neurotoxicity is reduced, as has been shown in the absence of D2R (Granado et al. 2011a ).
These results suggest that the neuroprotection observed in the absence of the D1 dopamine receptor depends primarily on the decrease in DA content and turnover rate, combined with lower cytosolic dopamine levels, rather than on hypothermia. In view of the results obtained previously, neuroprotective strategies that have proven effective against methamphetamine-induced dopaminergic neurotoxicity may be reasonably considered for use against MDMA and other amphetamine derivatives. Further, elucidation of the molecular mechanism of amphetamine toxicity may allow the development of better therapies to protect against the dopaminergic neurodegeneration that occurs after administration of drugs or in diseases such as Parkinson's disease.
